Cargando…

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban

Almost 800,000 new or recurrent strokes occur every year. Atrial fibrillation, the most common cardiac arrhythmia, is a major risk factor for stroke, accounting for 15-20% of ischemic strokes. Apixaban is a direct inhibitor of Factor Xa that was approved in December 2012 by the US Food and Drug Admi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mezue, Kenechukwu, Obiagwu, Chukwudi, John, Jinu, Sharma, Abhishek, Yang, Felix, Shani, Jacob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324317/ https://www.ncbi.nlm.nih.gov/pubmed/27450450 http://dx.doi.org/10.2174/1573403X12666160720092024

Ejemplares similares

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

Efficacy and Safety of Novel Oral Anticoagulants for Atrial Fibrillation Ablation: An Updated Meta-Analysis
por: Vallakati, Ajay, et al.
Publicado: (2016)

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
por: Kyriakou, Elias, et al.
Publicado: (2018)

The new oral anticoagulants in atrial fibrillation: an update
por: Verheugt, F. W. A.
Publicado: (2013)

Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation
por: Pillarisetti, Jayasree, et al.
Publicado: (2020)

Giant Left Atrial Thrombus Despite Anticoagulation with Apixaban in a Patient with Mitral Stenosis and Atrial Fibrillation
por: Turek, Łukasz, et al.
Publicado: (2021)

Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation
por: Seeger, Julia, et al.
Publicado: (2020)

Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban
por: DiNicolantonio, James J, et al.
Publicado: (2014)

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
por: Martin, Andrew, et al.
Publicado: (2012)

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014)

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2019)

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial
por: Pol, Tymon, et al.
Publicado: (2018)

Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants
por: Ng, Kuan H., et al.
Publicado: (2013)

Prevalence of oral anticoagulation in atrial fibrillation
por: Bartholomay, Eduardo, et al.
Publicado: (2014)

Pituitary Apoplexy in the Setting of Oral Anticoagulation Therapy With Apixaban
por: Rivera-Nieves, Yadiel, et al.
Publicado: (2021)

Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2022)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation
por: Spinthakis, Nikolaos, et al.
Publicado: (2019)

Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users
por: McHorney, Colleen A., et al.
Publicado: (2018)

The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
por: Lawrence, Matthew J., et al.
Publicado: (2022)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
por: Samoš, Matej, et al.
Publicado: (2022)

Satisfaction with oral anticoagulants in patients with atrial fibrillation
por: Suárez Fernández, Carmen, et al.
Publicado: (2018)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
por: Hallinen, Taru, et al.
Publicado: (2021)

COVID‐19 and the heart: An update for clinicians
por: Goha, Ahmed, et al.
Publicado: (2020)

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
por: Ioannou, Adam, et al.
Publicado: (2017)

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
por: Kirchhof, Paulus, et al.
Publicado: (2018)

Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation
por: Zhou, Meijia, et al.
Publicado: (2015)

Acute pulmonary edema secondary to hyperbaric oxygen therapy
por: Obiagwu, Chukwudi, et al.
Publicado: (2015)

Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
por: Zeymer, Uwe, et al.
Publicado: (2020)

Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2021)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Periprocedural anticoagulation in atrial fibrillation: Update on electrical cardioversion and ablation
por: van Vugt, S. P. G., et al.
Publicado: (2018)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Characterization of patients with atrial fibrillation not treated with oral anticoagulants
por: Johansson, Cecilia, et al.
Publicado: (2014)

Oral Anticoagulants for Atrial Fibrillation Patients with Active Cancer
por: Kim, Do Young, et al.
Publicado: (2018)

Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation
por: Giustozzi, Michela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5eptknerd191bq5eg3cshugiim